Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9
作者：
Sathananthan, Airani [1 ]
Vella, Adrian [1 ]
机构：
[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA
来源：
PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期
关键词：
OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;
D O I：
10.2217/PME.09.3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.
引用
收藏
页码：417 / 422
页数：6
相关论文
共 36 条
  • [31] Shannon H, 2000, NEW ENGL J MED, V342, P381
  • [32] Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
    Shu, Yan
    Sheardown, Steven A.
    Brown, Chaline
    Owen, Ryan P.
    Zhang, Shuzhong
    Castro, Richard A.
    Ianculescu, Alexandra G.
    Yue, Lin
    Lo, Joan C.
    Burchard, Esteban G.
    Brett, Claire M.
    Giacomini, Kathleen M.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) : 1422 - 1431
  • [33] Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Staels, B
    Fruchart, JC
    [J]. DIABETES, 2005, 54 (08) : 2460 - 2470
  • [34] Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159
  • [35] Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus
    Wang, G.
    Wang, X.
    Zhang, Q.
    Ma, Z.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (04) : 552 - 557
  • [36] Sequence variation in PPARG may underlie differential, response to Troglitazone
    Wolford, JK
    Yeatts, KA
    Dhanjal, SK
    Black, MH
    Xiang, AH
    Buchanan, TA
    Watanabe, RM
    [J]. DIABETES, 2005, 54 (11) : 3319 - 3325
1234